Loading…
Phibro Animal Health Corporation is projected to rise to $39.44 by 2027, a +16% move from its current price of $34.13. PAHC is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/7/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 8 | $33.30 | $34.15 | $35.02 | +0.05% |
| Jul 9 | $32.97 | $34.16 | $35.40 | +0.10% |
| Jul 10 | $32.73 | $34.18 | $35.70 | +0.15% |
| Jul 11 | $32.52 | $34.20 | $35.96 | +0.20% |
| Jul 12 | $32.35 | $34.22 | $36.19 | +0.25% |
| Jul 13 | $32.19 | $34.23 | $36.40 | +0.30% |
| Jul 14 | $32.05 | $34.25 | $36.60 | +0.35% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $32.05 | $34.25 | $36.60 | +0.35% |
| Week 2 | $31.29 | $34.37 | $37.76 | +0.71% |
| Week 3 | $30.74 | $34.49 | $38.70 | +1.06% |
| Week 4 | $30.31 | $34.61 | $39.53 | +1.42% |
| Week 5 | $29.94 | $34.74 | $40.30 | +1.77% |
| Week 6 | $29.62 | $34.86 | $41.02 | +2.13% |
| Week 7 | $29.34 | $34.98 | $41.70 | +2.49% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company with a global footprint that spans the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It runs three segments—Animal Health, Mineral Nutrition, and Performance Products—and develops, manufactures, and markets products for food and companion animals, including poultry, swine, beef and dairy cattle, aquaculture, and dogs.
The company offers animal health products such as antibacterials, anticoccidials, nutritional specialty products, and vaccines and vaccine adjuvants for animal health and performance, food safety, and welfare. It also engages in developing, manufacturing, and marketing microbial and bioproducts for animal health and nutrition, environmental, industrial, and agricultural applications, and produces vaccines and adjuvants for vaccine manufacturers. Further, it provides trace minerals to fortify livestock diets and offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries.
It sells its products through local sales offices and through commercial feed manufacturers, wholesalers, and distributors. Formerly Philipp Brothers Chemicals, Inc., the company changed its name to Phibro Animal Health Corporation in July 2003 and was incorporated in 1946; it is headquartered in Teaneck, New Jersey.
PAHC trades at $33.26 per share and has a market capitalization of $1.35B. It is ranked 2353 in the market. The stock shows a 30-day price range from $28.14 to $39.31, illustrating the near-term volatility around the current level.
Forecast data depict a rising path from 2026 through 2050, with the 2026 average at $33.26 and expanding over time to a 2030 average of $45.97, and a long-horizon average of $200.44 by 2050. Max forecast prices reach $360.77 in 2050, highlighting substantial long-run upside potential. The current technical backdrop features Neutral sentiment, RSI 50, SMA50 of $37.80, and SMA200 of $43.07, with support at $28.52 and resistance at $33.81.
The annualized volatility stands at 50%.
A major floor 21.9% below — a decisive break under it would weaken the trend.
The nearest floor, 16.4% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 74.6% above — clearing it would confirm fresh momentum.
Key PAHC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PAHC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $32.54 | Buy | $32.87 | Buy |
| MA 10 | $31.92 | Buy | $32.34 | Buy |
| MA 20 | $31.84 | Buy | $32.56 | Buy |
| MA 50 | $37.40 | Sell | $36.67 | Sell |
| MA 100 | $45.43 | Sell | $40.37 | Sell |
| MA 200 | $43.05 | Sell | $40.18 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 53.52 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 261.33 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.75 | Buy |
| ROC (12) | 7.09 | Buy |
| Bollinger %B (20,2) | 1.21 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -0.72 | Sell |
| Awesome (5,34) | 0.42 | Buy |
| Ultimate (7,14,28) | 74.75 | Sell |
| Momentum (10) | 2.28 | Buy |
| Aroon Osc (25) | 88.00 | Buy |
| Hull MA (9) | 33.22 | Buy |
| ADX (14) | 23.14 | Buy |
| ATR (14) | 0.84 | Info |
The 30-day technical picture suggests a neutral posture for PAHC, with the RSI at 50 indicating a balance between buying and selling pressure.
Key moving averages place the near term above the 50-day average at $37.80 (SMA50) and below the 200-day benchmark at $43.07 (SMA200), signaling mixed momentum near the current price. The stock sits between support at $28.52 and resistance at $33.81, with the 30-day range spanning $28.14 to $39.31.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $28.52 | $34.13 | $43.89 | 0% | Neutral | |
| $31.62 | $39.44 | $51.90 | +16% | Neutral | |
| $31.70 | $40.55 | $55.23 | +19% | Neutral | |
| $34.70 | $45.33 | $63.41 | +33% | Bullish | |
| $36.02 | $47.93 | $68.59 | +40% | Bullish | |
| $39.27 | $53.15 | $77.58 | +56% | Bullish | |
| $49.10 | $67.50 | $100.29 | +98% | Bullish | |
| $52.79 | $73.63 | $111.19 | +116% | Bullish | |
| $53.46 | $75.62 | $115.90 | +122% | Bullish | |
| $55.11 | $79.00 | $122.76 | +131% | Bullish | |
| $84.09 | $127.99 | $210.79 | +275% | Bullish | |
| $126.52 | $213.34 | $382.51 | +525% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $28.52 | $34.13 | $40.85 | +0.00% |
| August 2026 | $29.30 | $34.55 | $41.80 | +1.23% |
| September 2026 | $30.12 | $35.73 | $43.66 | +3.42% |
| October 2026 | $30.20 | $36.02 | $44.39 | +0.81% |
| November 2026 | $29.33 | $35.15 | $43.62 | -2.42% |
| December 2026 | $29.19 | $35.13 | $43.89 | -0.04% |
Click any year to see its month-by-month PAHC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The PAHC price prediction for 2026 points to an average of $34.13 (low $28.52, high $43.89) — a potential gain of 0% on today's $34.13. A consolidation phase looks the most probable path here.
In 2027, PAHC is projected to trade between $31.62 and $51.90, averaging $39.44 — a potential gain of +16% from today's $34.13. That is up +16% on the projected 2026 average. Price action looks broadly range-bound.
Phibro Animal Health Corporation's 2028 outlook centres on $40.55, within a $31.70 to $55.23 range. That is up +3% on the projected 2027 average. That marks a +19% change versus current levels. A consolidation phase looks the most probable path here.
By 2029, PAHC could reach as high as $63.41, with a base case around $45.33 and support toward $34.70 — roughly +33% from $34.13. Momentum favours further upside here.
Expect PAHC to range from $36.02 to $68.59 through 2030. The $47.93 average target implies a +40% move from current prices. That is up +6% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The PAHC price prediction for 2031 points to an average of $53.15 (low $39.27, high $77.58) — a potential gain of +56% on today's $34.13. Momentum favours further upside here.
In 2032, PAHC is projected to trade between $49.10 and $100.29, averaging $67.50 — a potential gain of +98% from today's $34.13. That is up +27% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Phibro Animal Health Corporation's 2033 outlook centres on $73.63, within a $52.79 to $111.19 range. That is up +9% on the projected 2032 average. That marks a +116% change versus current levels. Momentum favours further upside here.
By 2034, PAHC could reach as high as $115.90, with a base case around $75.62 and support toward $53.46 — roughly +122% from $34.13. Buyers look set to stay in control over this stretch.
Expect PAHC to range from $55.11 to $122.76 through 2035. The $79.00 average target implies a +131% move from current prices. That is up +4% on the projected 2034 average. Momentum favours further upside here.
The PAHC price prediction for 2040 points to an average of $127.99 (low $84.09, high $210.79) — a potential gain of +275% on today's $34.13. Buyers look set to stay in control over this stretch.
In 2050, PAHC is projected to trade between $126.52 and $382.51, averaging $213.34 — a potential gain of +525% from today's $34.13. That is up +67% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in PAHC today (≈ 29.299736 PAHC) could be worth
$6,250.69
+$5,250.69 (+525%) by 2050 · US Dollar
Based on the average projected PAHC price of $213.34 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PAHCwould be worth at today's price.
$1,000 invested in PAHC on Jul 7, 2025 (≈ 33.444816 PAHC) would be worth
$1,141.47
+$141.47 (+14.1%) today · 1.14× · US Dollar
Based on a PAHC entry price of $29.9 vs. today's $34.13.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $31.81 | $1,072.93 | +7.3% |
| 1 month ago | $32.43 | $1,052.42 | +5.2% |
| 3 months ago | $55.66 | $613.19 | -38.7% |
| 6 months ago | $39.43 | $865.58 | -13.4% |
| 1 year ago | $29.9 | $1,141.47 | +14.1% |
| All time (5.0y) ago | $25.53 | $1,336.86 | +33.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PAHC forecast.
Our base-case forecast reaches $68.00 around 2033.
Implied market cap at $68.00: $1.43B
Over the multi-year horizon, the forecast envisions a bullish trajectory from 2029 onward. The 2029 average is $43.72 with a max of $61.28 and a 31.4% ROI, followed by 2030 average of $45.97 (max $65.92) and an 38.2% ROI. By 2031 the average rises to $50.70 (max $74.18) with a 52.4% ROI, and 2032 shows an average of $64.65 (max $96.29) and a 94.4% ROI.
The ascent continues through 2033 at $70.28 (max $106.40) with 111.3% ROI, 2034 at $71.88 (max $110.46) with 116.1% ROI, and 2035 at $75.30 (max $117.35) with 126.4% ROI.
The path then extends to 2040 with an average of $121.00 (max $199.93) and a 263.8% ROI, and culminates in 2050 at an average of $200.44 (max $360.77) and a 502.6% ROI. These are estimates and not guarantees, and actual results may differ due to market conditions and other factors. The forecast implies meaningful long-run upside with bullish sentiment in the later years.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $45.97, with a max of $65.92 and a ROI of 38.2%; sentiment is BULLISH.
Forecasts indicate a long-run bullish trajectory, with 2027 avg $38.29 (ROI 15.1%), 2028 avg $39.15 (ROI 17.7%), 2029 avg $43.72 (ROI 31.4%), 2030 avg $45.97 (ROI 38.2%), 2040 avg $121.00 (ROI 263.8%), and 2050 avg $200.44 (ROI 502.6%). These are estimates and not guarantees.
Yes. The forecast shows a max of $106.40 in 2033, indicating PAHC could briefly exceed $100 in that year.
Current price is $33.26, and market capitalization is $1.35B; PAHC is ranked 2353.
The 2040 forecast shows an average price of $121.00 and a max of $199.93, with a ROI of 263.8% and bullish sentiment.
Phibro Animal Health Corporation Community Discussion
0Share your Phibro Animal Health Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.